Product Description
An extended-release (ER) formulation of APL-1501, an orally available inhibitor of methionine aminopeptidase II type (MetAP2), with potential antiangiogenic and antineoplastic activities. Upon administration, ER MetAP2 inhibitor APL-1501 is released from the formulation over an extended period of time and targets, binds to and reversibly inhibits MetAP2, thereby preventing MetAP2-mediated signal transduction pathways. This may suppress endothelial cell growth and inhibit tumor angiogenesis, resulting in tumor cell death. MetAP2, a member of the dimetallohydrolase family, is upregulated in certain tumor cell types and plays a key role in angiogenesis, proliferation and survival. Compared to APL-1202, APL-1501 has improved pharmacokinetic (PK) characteristics. The ER formulation allows for controlled drug release, enhanced drug plasma exposure time and reduced medication intake frequency. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/extended-release-metap2-inhibitor-apl-1501)
Mechanisms of Action: METAP2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Yahong Meditech
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Bladder Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| YHGT-APL1501-NHS-103 | P1 |
Not yet recruiting |
Bladder Cancer |
2024-08-21 |
44% |
| YHGT-PN-02 | P1 |
Not yet recruiting |
Bladder Cancer |
2024-01-19 |